Find research datasets worth reusing
Search datasets from major research repositories and use ShareScore to quickly assess how well each record supports discovery, access, and reuse.
4,582
datasets available to search
ShareScore release 0.9.0
Dataset results
4,582 results for “chronic diseases”
Study Exploring the Effect of Crizanlizumab on Kidney Function in Patients With Chronic Kidney Disease Caused by Sickle Cell Disease
ClinicalTrials.gov study NCT04053764. IPD Sharing: YES. Countries: 11. Publications: 2.
Activity, Safety and Pharmacokinetics in Pediatric Subjects With Moderate and Severe Chronic Graft vs. Host Disease After Allogeneic Stem Cell Transplant
ClinicalTrials.gov study NCT03774082. IPD Sharing: YES. Countries: 14. Publications: 1.
Evaluation of Renvela in Patients With Chronic Kidney Disease Not On Dialysis And Hyperphosphatemia In China
ClinicalTrials.gov study NCT03001011. IPD Sharing: YES. Countries: 1. Publications: 1.
Assessment of Glycemic Control in Patients With Type 2 Diabetes Mellitus and Late Stage Chronic Kidney Disease
ClinicalTrials.gov study NCT03383627. IPD Sharing: NO. Countries: 1. Publications: 4.
Whole Blood Platelet Aggregation in Chronic Kidney Disease Patients on Aspirin Study
ClinicalTrials.gov study NCT01768637. IPD Sharing: YES. Countries: 1. Publications: 2.
Proof-of-Concept Study to Assess the Efficacy, Safety and Tolerability of SAR440340 (Anti-IL-33 mAb) in Patients With Moderate-to-severe Chronic Obstructive Pulmonary Disease (COPD)
ClinicalTrials.gov study NCT03546907. IPD Sharing: YES. Countries: 10. Publications: 1.
Exposure to sugar rationing in the first 1000 days of life protected against chronic disease
Open the record for dataset details and reuse information.
Chronic wasting disease alters the movement behavior and habitat use of mule deer during clinical stages of infection
Open the record for dataset details and reuse information.
Data from: The impact of long-term azithromycin on antibiotic resistance in HIV-associated chronic lung disease
Open the record for dataset details and reuse information.
Data from: Age estimation using methylation-sensitive high-resolution melting (MS-HRM) in both healthy felines and those with chronic kidney disease
Open the record for dataset details and reuse information.
Deep learning chronic wasting disease (CWD) immunohistochemistry (IHC) image dataset
Open the record for dataset details and reuse information.
Figure 1. from: Acoustic biomarkers of Chronic Obstructive Lung Disease - Research Ideas and Outcomes 2: e9173 (11 May 2016) https://doi.org/10.3897/rio.2.e9173
Figure 1. - Poster as it was presented at the conference. Please see text for details.
Modelling data for: Short-course combination treatment for experimental chronic Chagas disease
<p><span>Chagas disease, caused by the protozoan parasite <em>Trypanosoma</em> <em>cruzi</em>, affects millions of people in the Americas and across the world leading to considerable morbidity and mortality. Current treatment options, benznidazole (BNZ) and nifurtimox, offer limited efficacy and often lead to adverse side effects due to long treatment durations. Better treatment options are therefore urgently required. Here we describe a pyrrolopyrimidine series, identified through phenotypic screening, that offers a clear opportunity to improve on current treatments. In vitro cell-based washout assays demonstrate that compounds in the series are incapable of killing all parasites, however, combining these pyrrolopyrimidines with a sub-efficacious dose of BNZ can clear all parasites in vitro after five days. Importantly, these findings were replicated in a clinically predictive<em> in vivo</em> model of chronic Chagas disease, where five days of treatment with the combination was sufficient to prevent parasite relapse. Comprehensive mechanism of action studies, supported by ligand-structure modelling, show that compounds from this pyrrolopyrimidine series inhibit the Q</span><sub><span>i</span></sub><span> active site of <em>T. cruzi</em> cytochrome <em>b</em>, part of the cytochrome <em>bc1</em> complex of the electron transport chain. Knowledge of the molecular target enabled a cascade of assays to be assembled to evaluate selectivity over the human cytochrome <em>b</em> homologue. As a result, a highly selective and efficacious lead compound was identified. The combination of our lead compound with BNZ rapidly clears<em> T. cruzi</em> parasites, both <em>in vitro</em> and <em>in vivo</em>, and shows great potential to overcome key issues associated with currently available treatments. </span></p>
Identifying biomarkers for chronic obstructive pulmonary disease in the salivary metabolome.
<p><strong><span>Background:</span></strong><span> The lack of specificity in spirometry and accuracy in ‘pre-disease states’, and elderly indicates the need for other accurate, inexpensive and non-invasive tests for diagnosis, triage severity and particularly for choosing and monitoring response to treatments in chronic obstructive pulmonary disease (COPD). We compared salivary metabolomic signatures from patients with COPD and controls across a range of severity of airflow obstruction. </span></p> <p><a name="_61k4y1plsv5"></a><strong><span>Methods</span></strong></p> <p><span>45 people with COPD (mean age 66.1 ± 23 years, forced expiratory volume [FEV<sub>1</sub>] 47<u>+</u>15% predicted) and 48 healthy controls (mean age 56.0 <u>+</u>16.2 years, FEV<sub>1</sub> 90<u>+</u>23 % predicted) provided saliva that was assessed by flow infusion electrospray mass spectrometry (FIE-MS). Spectra were interrogated using an online library package. Data (patient data and metabolomic outputs) are available from this site. </span></p> <p><a name="_j99pcjszp0an"></a><strong><span>Results</span></strong></p> <p><span>Four potential biomarkers identified the presence of COPD with a sensitivity of 73%, specificity of 72%.<span> </span>Six metabolites predicted FEV1 % in the COPD cohort (<em>P </em>< 0.001, R<sup>2</sup> > 0.3, AUC > 0.7) whilst a range of multivariate approaches targeted six metabolites linked to GOLD stage (<em>P </em>< 0.001, AUC > 0.7). Identification of the metabolites suggested changes in pterin biosynthesis, lipid processing, nucleotide metabolism and melatonin in COPD patients. </span></p> <p><a name="_2n4ucvxs4l1n"></a><strong><span>Conclusions</span></strong></p> <p><span>Metabolic fingerprinting of saliva samples could differentiate COPD from age matched controls and inform COPD severity of airflow obstruction. Potential biomarkers are suggested which could inform the diagnosis and monitoring of COPD.</span></p> <p><span> </span></p> <h2><span> </span></h2>
Characterizing Metabolic Alterations in Early-stage chronic kidney disease (CKD) patients: A Pathway for Improved Diagnosis and Personalized Treatment.
<p>The raw NMR data that I have uploaded contains the final concentration results that have been used for this study.</p>
Expanding drug targets for 112 chronic diseases using a machine learning-assisted genetic priority score
<h2>ML-GPS: Machine Learning-Assisted Genetic Priority Score</h2> <p>This Zenodo repository contains data and code associated with the publication:</p> <p>Chen R, Duffy Á, Petrazzini BO, Vy HM, Stein D, Mort M, Park JK, Schlessinger A, Itan Y, Cooper DN, Jordan DM, Rocheleau G, Do R. Expanding drug targets for 112 chronic diseases using a machine learning-assisted genetic priority score. Nat Commun. 2024 Oct 15;15(1):8891. doi: <a href="https://doi.org/10.1038/s41467-024-53333-y">10.1038/s41467-024-53333-y</a>.</p> <h3>Important notes</h3> <ul> <li>You can interactively view the top 10% of ML-GPS predictions without download at <a href="https://rstudio-connect.hpc.mssm.edu/mlgps/">https://rstudio-connect.hpc.mssm.edu/mlgps/</a>.</li> <li>For running Jupyter notebooks, please follow the instructions in the README of the GitHub repository at <a href="https://github.com/robchiral/ML-GPS">https://github.com/robchiral/ML-GPS</a>.</li> </ul> <h3>Repository contents</h3> <p>Files needed to train ML-GPS and ML-GPS DOE:</p> <ul> <li><strong>Files needed for Jupyter notebooks.zip</strong>: Data files required for preprocessing and training.</li> <li><strong>Jupyter notebooks.zip</strong>: Notebooks for cleaning data, training models, and generating predictions.</li> </ul> <h3>Other files:</h3> <ul> <li><strong>Predictions for all gene-phecode pairs.zip</strong>: ML-GPS and ML-GPS DOE scores for all analyzed gene-phecode pairs.</li> <li><strong>Summary statistics.zip</strong>: Genetic association summary statistics for all tested gene-phecode pairs.</li> </ul> <h3>Updated performance metrics</h3> <table> <tbody> <tr> <td><strong>Model</strong></td> <td><strong>Open Targets AUPRC</strong></td> <td><strong>SIDER AUPRC</strong></td> </tr> <tr> <td>ML-GPS (non-DOE)</td> <td>0.074</td> <td>0.080</td> </tr> <tr> <td>ML-GPS DOE (activator predictions)</td> <td>0.029</td> <td>0.042</td> </tr> <tr> <td>ML-GPS DOE (inhibitor predictions)</td> <td>0.067</td> <td>0.064</td> </tr> </tbody> </table> <h3>Zenodo versions</h3> <ul> <li><strong>Version 4: </strong>Updated notebooks and external data to use Open Targets 2024.9; summary statistics are unchanged</li> <li><strong>Version 3: </strong>Corrected error where DOE for rare and ultrarare variants was incorrectly incorporated</li> <li><strong>Version 2: </strong>Original release accompanying the publication</li> </ul>
data set regarding to project Optimal assessment of nutritional status in older subjects with the chronic obstructive pulmonary disease
<p>data set regarding to project Optimal assessment of nutritional status in older subjects with the chronic obstructive pulmonary disease</p>
data set regarding to project Optimal assessment of nutritional status in older subjects with the chronic obstructive pulmonary disease – a comparison of three screening tools used in the GLIM diagnostic algorithm
<p>data set regarding to project Optimal assessment of nutritional status in older subjects with the chronic obstructive pulmonary disease – a comparison of three screening tools used in the GLIM diagnostic algorithm </p>
Hematopoietic Tumors in a Mouse Model of X-linked Chronic Granulomatous Disease after Lentiviral Vector-Mediated Gene Therapy
<p>Chronic granulomatous disease (CGD) is a rare inherited disorder due to loss-of-function mutations in genes encoding the NADPH oxidase subunits. Hematopoietic stem and progenitor cell (HSPC) gene therapy (GT) using regulated lentiviral vectors (LVs) has emerged as a promising therapeutic option for CGD patients. We performed non-clinical Good Laboratory Practice (GLP) and laboratory-grade studies to assess the safety and genotoxicity of LV targeting myeloid specific Gp91phox expression in X-linked chronic granulomatous disease (XCGD) mice. We found persistence of gene-corrected cells for up to 1 year, restoration of Gp91phox expression and NADPH oxidase activity in XCGD phagocytes, and reduced tissue inflammation after LV-mediated HSPC GT.<br> Although most of the mice showed no hematological or biochemical toxicity, a small subset of XCGD GT mice developed<br> T cell lymphoblastic lymphoma (2.94%) and myeloid leukemia (5.88%). No hematological malignancies were identified in C57BL/6 mice transplanted with transduced XCGD HSPCs. Integration pattern analysis revealed an oligoclonal composition with rare dominant clones harboring vector insertions near oncogenes in mice with tumors. Collectively, our data support the long-term efficacy of LV-mediated HSPC GT in XCGD mice and provide a safety warning because the chronic inflammatory XCGD background may contribute to oncogenesis.</p>
CHRONIC KIDNEY DISEASE SCREENING IN COMMUNITY PHARMACY: CRIERFAC PROJECT
<p>Chronic kidney disease (CKD) is a major health problem. Early detection improves the prognosis of these patients, but the disease does not show its face until it is more advanced. The aim is to screen for the disease in community pharmacies in order to refer patients to primary care physicians.</p> <p>Data from the 2116 patients recruited are presented in a single Excel table where each line corresponds to one patient. It contains patient demographics data, risk factors for chronic kidney disease, creatinine and glomerular filtration data, pharmacist intervention and physician response.</p>
ScienceDex guides
Understand access before you commit
These curated guides explain access requirements, typical timelines, costs, and reuse considerations for widely used research datasets.
Allen Brain Atlas
Allen Brain Atlas is an Allen Institute collection of brain map atlases, datasets, APIs, and analysis tools covering mouse, human, and non-human primate brain resources.
Annotated Behaviour and Observability Dataset (ABODe)
ABODe is a University of Edinburgh DataShare dataset for behavior classification in group-housed mice using home-cage video, identities, bounding boxes, ground-plate positions, and annotator labels.
DANDI Archive for NWB datasets
DANDI is a BRAIN Initiative archive for publishing and sharing neurophysiology data, including electrophysiology, optophysiology, and behavioral data packaged as NWB and related standards.
International Brain Laboratory public data
The International Brain Laboratory public data releases expose standardized mouse decision-making experiments, including Neuropixels recordings, widefield calcium imaging, behavior, and session metadata accessed through the ONE API.
OpenNeuro
OpenNeuro is a free, open platform for sharing neuroimaging datasets, with public search, dataset pages, and download paths for web, S3, DataLad, and the OpenNeuro CLI.